
Idexx Laboratories statistics
$704.23+0.89%Close 13 Nov 2026 · Market value $55.66B
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
Idexx Laboratories is valued at $55.66B on its latest close. Its price is 47.1 times its earnings.
| Market value | $55.66B |
|---|
| Enterprise value | $55.79B |
|---|
| Price / earnings | 47.08 |
|---|
| Price / sales | 11.94 |
|---|
| Price / book | 29.78 |
|---|
| EV / EBITDA | 33.52 |
|---|
| EV / sales | 11.97 |
|---|
| Price / free cash flow | 42.69 |
|---|
| Price / free cash flow, own 5-year average | 59.81 |
|---|
| EV / EBIT | 37.16 |
|---|
| EV / free cash flow | 42.92 |
|---|
| Free cash flow yield | 2.3% |
|---|
Share price
| Latest close | $704.23 |
|---|
| Day's change | +0.9% |
|---|
| 52-week high | $769.98 |
|---|
| 52-week low | $500.61 |
|---|
| From 52-week high | −8.5% |
|---|
| Return · 1 month | +25.7% |
|---|
| Return · 3 months | +29.0% |
|---|
| Return · year to date | +4.1% |
|---|
| Return · 1 year | −1.3% |
|---|
| Beta · 1 year against the S&P 500 | 0.82 |
|---|
| 50-day average | $562.41 |
|---|
| 200-day average | $572.35 |
|---|
| RSI 14 | 71.6 |
|---|
| Average volume · 20 sessions | 684K |
|---|
Margins and returns
For fiscal 2025, as filed.
| Gross margin | 61.8% |
|---|
| Operating margin | 31.6% |
|---|
| Net margin | 24.6% |
|---|
| Free cash flow margin | 24.6% |
|---|
| Return on equity | 66.2% |
|---|
| Return on assets | 32.8% |
|---|
| Return on invested capital | 50.4% |
|---|
| Return on invested capital, 5-year average | 46.9% |
|---|
| Return on capital employed | 61.4% |
|---|
| Stock-based compensation / revenue | 1.4% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $180.1M |
|---|
| Total debt | $578.1M |
|---|
| Net debt | $398.0M |
|---|
| Current ratio | 1.23 |
|---|
| Quick ratio | 0.64 |
|---|
| Debt / equity | 0.36 |
|---|
| Net debt / EBITDA | 0.26 |
|---|
| Interest coverage | 35.01 |
|---|
Growth
| Revenue, latest quarter on a year | +9.9% |
|---|
| Revenue, twelve months on a year | +11.9% |
|---|
| EPS, latest quarter on a year | +17.9% |
|---|
| EPS, twelve months on a year | +17.6% |
|---|
| Revenue, 5-year compound | +9.7% |
|---|
| Revenue, 10-year compound | +10.4% |
|---|
| Net income, 5-year compound | +12.7% |
|---|
| Free cash flow, 5-year compound | +14.3% |
|---|
| EPS, 5-year compound | +14.3% |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 81.0M |
|---|
| Shares outstanding, 5-year compound | −1.3% |
|---|
| Net share repurchases | $1.12B |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $264.7M |
|---|
| Effective tax rate | 20.0% |
|---|
IDXX in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.